EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

Tara L Peters, Nan Chen iD, Logan C Tyler, Anh T Le, Anastasios Dimou, Robert C Doebele

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Tara L Peters und 5 weiteren Autor:innen. Beteiligte Einrichtung: Enliven Therapeutics, Inc., Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Axl Receptor Tyrosine Kinase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinical benefit and demonstrate rapid disease progression. The biological mechanisms underpinning intrinsic resistance remain poorly understood for oncogene‐driven cancers.

Methods

We generated a patient‐derived cell line, CUTO33, from a ROS1 therapy naive patient with CD74‐ROS1+ NSCLC, who ultimately did not respond to a ROS1 inhibitor. We evaluated a panel of ROS1+ patient‐derived NSCLC cell lines and used cell‐based assays to determine the mechanism of intrinsic resistance to ROS1 therapy.

Results

The CUTO33 cell line expressed the CD74‐ROS1 gene fusion at the RNA and protein level. The ROS1 fusion protein was phosphorylated at baseline consistent with the known intrinsic activity of this oncogene. ROS1 phosphorylation could be inhibited using a wide array of ROS1 inhibitors, however these inhibitors did not block cell proliferation, confirming intrinsic resistance in this model and consistent with the patient's lack of response to a ROS1 inhibitor. CUTO33 expressed high levels of AXL, which has been associated with drug resistance. Combination of an AXL inhibitor or AXL knockdown with a ROS1 inhibitor partially reversed resistance.

Conclusions

In summary, we demonstrate that AXL overexpression is a mechanism of intrinsic resistance to ROS1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAxl Receptor Tyrosine KinaseHumansDrug Resistance, NeoplasmProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsOncogene Proteins, FusionTyrosine Kinase InhibitorsAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class II

Stichwörter der Autor:innen

AXLNSCLCROS1drug resistance

Substanzen

Protein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsOncogene Proteins, FusionAxl Receptor Tyrosine KinaseTyrosine Kinase InhibitorsROS1 protein, humaninvariant chainAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class II

Autor:innen und Institutionen

  • Enliven Therapeutics, Inc., Boulder, Colorado, USA.
  • Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • OnKure Therapeutics, Inc., Boulder, Colorado, USA.
  • Cell Technologies Shared Resources, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

ORCID-Profile: Nan Chen

Förderung

  • NCI NIH HHS

Zitieren

APA

Peters, T. L., Chen, N., Tyler, L. C., Le, A. T., Dimou, A., & Doebele, R. C. (2023). Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15116

Vancouver

Peters TL, Chen N, Tyler LC, Le AT, Dimou A, Doebele RC. Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15116

BibTeX
@article{Peters2023,
  author = {Peters, Tara L and Chen, Nan and Tyler, Logan C and Le, Anh T and Dimou, Anastasios and Doebele, Robert C},
  title = {Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15116}
}
Kostenlos starten →